PMID- 29288725
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20231112
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 666
DP  - 2018 Feb 14
TI  - Both ketamine and NBQX attenuate alcohol drinking in male Wistar rats.
PG  - 175-180
LID - S0304-3940(17)31025-X [pii]
LID - 10.1016/j.neulet.2017.12.055 [doi]
AB  - The devastating consequences of alcohol-use disorder (AUD) on the individual and 
      the society are well established. Current treatments of AUD encompass various 
      strategies, all of which have only modest effectiveness. Hence, there is a 
      critical need to develop more efficacious therapies. Recently, specific 
      glutamatergic receptors have been identified as potential novel targets for 
      intervention in AUD. Thus, the current study was designed to evaluate the effects 
      of acute administration of sub-anesthetic doses of ketamine, an NMDA receptor 
      antagonist, as well as NBQX, an AMPA/kainate receptor antagonist on alcohol 
      intake and its possible behavioural consequences. Adult male Wistar rats were 
      trained in drinking in dark paradigm (3 weeks), and following stable alcohol 
      intake, ketamine, NBQX as well as their combination were injected prior to a 
      90 min drinking session. In addition to alcohol intake, sucrose preference 
      (overnight), and locomotor activity and forced swim test (FST) were also 
      evaluated before and following alcohol intake. Both doses of ketamine (5 and 10 
      mg/kg) and NBQX (5 and 10 mg/kg) significantly attenuated percent alcohol intake. 
      The combination of the higher dose of ketamine and NBQX, however, did not 
      significantly affect percent alcohol intake. Moreover, animals exposed to alcohol 
      showed decreased sucrose intake (reflective of anhedonia), decreased locomotor 
      activity and swimming in the FST (reflective of helplessness), that were not 
      affected by ketamine and/or NBQX. These results suggest that selective antagonism 
      of the NMDA or AMPA/kainate receptors may be of therapeutic potential in AUD.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Ruda-Kucerova, Jana
AU  - Ruda-Kucerova J
AD  - Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech 
      Republic. Electronic address: jkucer@med.muni.cz.
FAU - Babinska, Zuzana
AU  - Babinska Z
AD  - Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech 
      Republic.
FAU - Luptak, Matej
AU  - Luptak M
AD  - Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech 
      Republic.
FAU - Getachew, Bruk
AU  - Getachew B
AD  - Department of Pharmacology, Howard University College of Medicine, Washington, 
      DC, USA.
FAU - Tizabi, Yousef
AU  - Tizabi Y
AD  - Department of Pharmacology, Howard University College of Medicine, Washington, 
      DC, USA.
LA  - eng
GR  - R03 AA022479/AA/NIAAA NIH HHS/United States
GR  - U54 HD090257/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171228
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Quinoxalines)
RN  - 0 (Receptors, AMPA)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 118876-58-7 (2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline)
RN  - 690G0D6V8H (Ketamine)
RN  - SIV03811UC (Kainic Acid)
SB  - IM
MH  - Alcohol Drinking/*adverse effects
MH  - Animals
MH  - Depression/*drug therapy
MH  - Kainic Acid/pharmacology
MH  - Ketamine/*pharmacology
MH  - Male
MH  - Quinoxalines/*pharmacology
MH  - Rats, Wistar
MH  - Receptors, AMPA/*antagonists & inhibitors
MH  - Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
PMC - PMC5805612
MID - NIHMS932120
OTO - NOTNLM
OT  - AMPA receptor
OT  - Alcohol use disorder
OT  - Alcoholism
OT  - Glutamatergic receptors
OT  - Kainate receptor
OT  - NMDA receptor
COIS- Statement of interest statement None declared.
EDAT- 2017/12/31 06:00
MHDA- 2018/12/12 06:00
PMCR- 2019/02/14
CRDT- 2017/12/31 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2017/12/22 00:00 [revised]
PHST- 2017/12/23 00:00 [accepted]
PHST- 2017/12/31 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/12/31 06:00 [entrez]
PHST- 2019/02/14 00:00 [pmc-release]
AID - S0304-3940(17)31025-X [pii]
AID - 10.1016/j.neulet.2017.12.055 [doi]
PST - ppublish
SO  - Neurosci Lett. 2018 Feb 14;666:175-180. doi: 10.1016/j.neulet.2017.12.055. Epub 
      2017 Dec 28.